In the Claims

Please Cancel Claims 8-10 inclusive and Cancel Claims 12-21 inclusive, without prejudice to the filing of future continuing applications.

Please add the following NEW Claims 22-27.

Please rewrite the following claims 1-7 and 11 to read as follows:

1. (Amended) A method for lowering the concentration of glycosylated hemoglobin in a mammal in need thereof, which comprises administering to said mammal an effective amount of an insulin sensitizer in combination with an anorectic.

2. (Amended) The method according to claim 1, wherein the insulin sensitizer is a compound of the formula:



wherein R represents a hydrocarbon group or a heterocyclic group, each of which may be substituted; Y represents a group of the formula: -CO-, -CH(OH)- or -NR^3- where R^3 represents an alkyl group that may be substituted; m is 0 or 1; n is 0, 1 or 2; X represents CH or N; A represents a chemical bond or a bivalent aliphatic hydrocarbon group having 1 to 7 carbon atoms; Q represents oxygen or sulfur; R^1 represents hydrogen or an alkyl group; ring E may have further 1 to 4 substituents, which may form a ring in combination with R^1; L and M respectively represent hydrogen or may be combined with each other to form a chemical bond; or a salt thereof.

3. (Amended) The method according to claim 1, wherein the insulin sensitizer is pioglitazone, troglitazone, rosiglitazone, 4-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzyl]isoxazolidin-3,5-dione, 5-[[6-(2-fluorobenzyloxy)-2-naphthyl]methyl]-2,4-thiazolidinedione or their salts.

4. (Amended) The method according to claim 2, wherein the compound of the formula (I) or salt thereof is pioglitazone hydrochloride.

5. (Amended) The method according to claim 1, wherein the anorectic is a β-adrenaline receptor agonist. – mazindol & sibutramine

A2

6. (Amended) The method according to claim 5, wherein the β-adrenaline receptor agonist is mazindol.

7. (Amended) The method according to claim 1, wherein the insulin sensitizer is pioglitazone hydrochloride and the anorectic is mazindol.

A3

11. (Amended) The method according to claim 2 , wherein the compound of the formula (I) or salt thereof is rosiglitazone or its maleate. no amide

A4

22. (new) The method according to claim 1, wherein the anorectic is selected from the group consisting of α-adrenaline receptor antagonists, β-adrenaline receptor agonists (mazindol), dopamine receptor agonists, serotonin receptor agonists, 5-HT agonists, cimetidine and ergoset.

23. (new) The method according to claim 1, wherein the anorectic is selected from the group consisting of leptin and its analogues; leptin receptor agonists; leptin resistance-improving agents; neuropeptide Y antagonists; cholecystokinin agonists; glucagon-like peptide 1 or its analogues or its agonists; galannin antagonist; glucagon agonists; melanin-concentrating hormone agonists; melanocortin agonists; enterostatin agonists; tripeptidylpeptidase II inhibitors; and corticotropin releasing hormone or its analogues or its agonists.

24. (new) The method according to claim 1, wherein the anorectic is sibutramine.

25. (new) The method according to claim 1, wherein the insulin sensitizer is pioglitazone or its salt, and the anorectic is sibutramine.

A4

26. (new) The method according to claim 1, wherein the insulin sensitizer and the anorectic are administered to the mammal concomitantly.

27. (new) The method according to claim 1, wherein the insulin sensitizer and the anorectic are administered to the mammal separately.